Physician profile
Curtis E Grey
NPI 1962404756
$520.08
in general payments reported to CMS, 2019-2025
16 companies · $34.79 in 2025
The $34.79 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2022: $22.31 · 2024: $25.10 · 2025: $34.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $96.02 | 2019 | |
| Amgen INC. | $72.80 | 2019 | |
| Novo Nordisk INC | $66.02 | 2019 | |
| Merck Sharp & Dohme LLC | $56.56 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $26.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.94 | 2019 | |
| Coopersurgical, INC. | $25.10 | 2024 | Paragard T 380a |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.31 | 2022 | |
| Abbvie INC. | $20.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.74 | 2019 | |
| Evofem Biosciences, INC. | $18.49 | 2025 | Solosec, Phexx, Phexxi |
| Supernus Pharmaceuticals, INC. | $16.30 | 2025 | Qelbree |
| Allergan, INC. | $15.38 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.43 | 2019 | |
| Astellas Pharma US INC | $13.10 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Grey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.